CHRONIX BIOMEDICAL, INC

Chronix Biomedical, Inc. is a molecular diagnostics company offering laboratory developed tests for cancer.

CNI MONITOR

CNI Monitor

Provides earliest determination of the efficacy of cancer therapies.

CNI MONITOR

CNI Screen

Can provide an indication that a malignancy may be present in an asymptomatic individual.

CNI MONITOR

CNI 2nd Opinion

Assists in reducing unnecessary biopsies and improves patient care.

All Chronix tests are blood tests (Liquid biopsy tests) which detect tumor-derived cell-free DNA in blood samples of patients. Gains and losses of large chromosome sections that are present in the genome of cancer cells are detected and combined in a comprehensive copy number instability (CNI) score that can indicate tumor existance, remission or progression. Chronix blood tests are suitable for therapy monitoring for patients with chemotherapy or immunotherapy and for relapse monitoring after tumor resection (CNI MONITOR), screening (CNI SCREEN) and/or 2nd opinion regarding eventual tissue biopsis (CNI 2nd OPINION).

WHY OUR TESTS ARE SO EFFECTIVE?

CHRONIX NEWS

Early detection of cancer – why is it important?

The number of people diagnosed with tumors, especially malignant ones, is constantly increasing. There is also a rise in mortality rate due to delayed diagnosis and inappropriate [...]

  • chronix asco news

It was the 5th year that Chronix Biomedical has been present at ASCO Annual Meeting in Chicago

This was the busiest ASCO conference yet for Chronix Biomedical. Chronix booth was visited by clinical trial oncologists, international cancer research...

  • pancreatic cancer

Chronix Biomedical reports positive interim pancreatic cancer data

Chronix Biomedical reports a positive interim analysis of its ongoing validation study of its Copy Number Instability (CNI)-based therapeutic monitoring test in pancreatic cancer. The study compares the accuracy of Chronix’s CNI-based test at predicting a clinical response, as early as after the first cycle of chemotherapy compared to CA19-9, a commonly used biomarker.

Chronix Biomedical presents positive data on prognostic test in head/neck cancer study data at ASCO

Study finds CNI score to be a stronger predictor of time to recurrence in head and neck cancer than current method based on lymph node invasion. The study enrolled 54 patients undergoing surgery for this cancer type and evaluated the Chronix test as a predictor of time to progression in comparison with the current method based on the degree of tumour invasion of lymph nodes (pN status).

  • Chronix Biomedical

Chronix Biomedical is pleased to be a sponsor of the PCRT annual meeting

Chronix Biomedical

Chronix looks forward to working with this team of international pancreatic cancer experts.

  • ASCO 2017

Chronix at the ASCO 2017 Annual Meeting

Chronix Biomedical

This is the third year that Chronix is presenting its study results at ASCO — this year’s results are from a blinded prospective study validating the use of a CNI Monitor blood test to predict the treatment outcome of patients undergoing immunotherapy.

VIDEOS

Madappa N. Kundranda, MD, PhD. Director, Gastrointestinal Oncology Program, Adjunct Assistant Professor, University of Texas MD Anderson Cancer Center,Banner MD Anderson, Arizona.

Experts on Chronix Biomedical CNI Monitor test. Testing for drug efficacy. #TheTurningPointInCancerFight

Chronix ASCO 2017: Dr Glen Weiss

Experts on Chronix Biomedical CNI Monitor test. Testing for drug efficacy. #TheTurningPointInCancerFight

Chronix ASCO 2017: Dr Tomislav Dragovich

Experts on Chronix Biomedical CNI Monitor test. Testing for drug efficacy. #TheTurningPointInCancerFight

MEDICAL PUBLICATIONS

  • Dr hab. n. med. Jakub Dobruch FEBU - liquid biopsy

Cell-free DNA for treatment monitoring and outcome predictor in head and neck cancer

Chronix Biomedical presents positive data on prognostic test in head/neck cancer study data at ASCO. Study finds CNI score to be a stronger predictor of time to recurrence in head and neck cancer than current method based on lymph node invasion.

  • liquid biopsy - Chronix Biomedical

Predicting Treatment Outcomes in Immunotherapy

Weiss, G. et al. Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy.

Genomic analysis of tissue malignancies is well recapitulated by tumor cell free DNA (cfDNA) using the power of Next Generation Sequencing (NGS).

  • predicting-treatment-outcomes-in-chemotherapy

Predicting Treatment Outcomes in Chemotherapy

Weiss, Glen J., et al. Changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response in metastatic cancers. Cancer Research 76.14 Supplement (2016): 3138-3138.

Gains and losses of chromosomal regions – as a hallmark of cancer – have been detected in plasma as copy number aberrations (CNAs), and for several cancers a relation to tumor size has been reported.

EVENTS

  • chronix asco news

It was the 5th year that Chronix Biomedical has been present at ASCO Annual Meeting in Chicago

This was the busiest ASCO conference yet for Chronix Biomedical. Chronix booth was visited by clinical trial oncologists, international cancer research...

  • Cancer Diagnostics laboratory

Advanced Cancer Diagnostics Showcasing at 2016 NCRI Cancer Conference 6-9 November 2016

Chronix Biomedical’s Ireland & UK distributors Advanced Cancer Diagnostics will be attending and showcasing the latest Chronix diagnostic tests: Second Opinion CNI Prostate Cancer Test, Second Opinion [...]

ORDER TESTS

Go to Modern Cancer Diagnostics or Advanced Cancer Diagnostics to order our tests

DOCTORS ABOUT OUR TESTS

“The knowledge that we have gained over the past year now suggests to us that we are able to provide to doctors and their patients the ability to diagnose at the most earliest stage the presence of cancer in their body.”
Howard Urnovitz, CEO of Chronix Biomedical for The Times
“We believe our cancer blood tests will lead to a world where no one dies unnecessarily of cancer.”
Howard Urnovitz, CEO of Chronix Biomedical